10x Genomics EBITDA margin
What is the EBITDA margin of 10x Genomics?
The EBITDA margin of 10x Genomics, Inc. is -18.54%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to 10x Genomics
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Companies with ebitda margin similar to 10x Genomics
- Conversion Labs has EBITDA margin of -18.74%
- Central Petroleum has EBITDA margin of -18.72%
- KK Culture has EBITDA margin of -18.63%
- Tortoise Power and Infrastructure Fund has EBITDA margin of -18.63%
- Sintex Plastics Technology has EBITDA margin of -18.61%
- Malachite Resources has EBITDA margin of -18.58%
- 10x Genomics has EBITDA margin of -18.54%
- Northeast Electric Development has EBITDA margin of -18.54%
- Horizon Discovery plc has EBITDA margin of -18.54%
- Lake Resources N.L has EBITDA margin of -18.53%
- Farfetch Ltd has EBITDA margin of -18.53%
- Lannett Co has EBITDA margin of -18.41%
- Parazero has EBITDA margin of -18.39%